Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Efficacy of SAL056 (Recombinant Human Parathyroid Hormone [1-34] for Injection [56.5 μg]) at Different Doses and Dosing Regimens: A Multicenter, Randomized, Open-Label, Parallel-Controlled Phase II Clinical Trial

NCT07579936 is registered in ClinicalTrials.gov with Shenzhen Salubris Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07579936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07579936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Efficacy of SAL056 (Recombinant Human Parathyroid Hormone [1-34] for Injection [56.5 μg]) at Different Doses and Dosing Regimens: A Multicenter, Randomized, Open-Label, Parallel-Controlled Phase II Clinical Trial
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2026
Completion date
November 30, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal women with osteoporosis